Kodiak Sciences Inc. reported financial results for the quarter ended June 30, 2026, posting a net loss of $65.6 million, or $1.05 per share, compared to a net loss of $54.3 million in the prior year period. The company held $125.9 million in cash and cash equivalents at quarter-end, which management expects will fund operations into 2027. Research and development expenses increased to $56.1 million from $42.8 million, driven by clinical activities for PEAK/PINNACLE studies and manufacturing for Phase 3 programs. General and administrative expenses decreased to $10.8 million from $12.8 million. The company highlighted key operational milestones, including the completion of enrollment for the first 300-patient cohort in the Phase 3 PEAK study for KSI-101 and the initiation of patient enrollment in the global Phase 3 ALTO study for KSI-501 in diabetic macular edema. Topline data from the Phase 3 DAYBREAK study evaluating Zenkuda and KSI-501 in wet AMD is expected in September 2026, while PEAK Pivotal Analysis 1 topline results are anticipated in December 2026. Kodiak Sciences Inc. operates in the biotechnology industry, focusing on researching, developing, and commercializing transformative therapeutics for retinal diseases.